Prelude Therapeutics Inc - PRLD
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Jul 08, 2026 | SCHEDULE 13G | Soleus Private Equity Fund III, L.P. | 1.0% | 675,676 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus Private Equity GP III, LLC | 1.0% | 675,676 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus PE GP III, LLC | 1.0% | 675,676 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus Capital Master Fund, L.P. | 4.2% | 2,702,702 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus Capital, LLC | 4.2% | 2,702,702 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus Capital Group, LLC | 4.2% | 2,702,702 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus Capital Management, L.P. | 5.2% | 3,378,378 | View |
| Jul 08, 2026 | SCHEDULE 13G | Soleus GP, LLC | 5.2% | 3,378,378 | View |
| Jul 08, 2026 | SCHEDULE 13G | Levy Guy | 5.2% | 3,378,378 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.